The neurologist at Mayo Clinic in Phoenix, Arizona, detailed whether her and colleagues recent study results on ubrogepant aligned with previous study findings.
“Additionally, consistent relief of pain for all treated attacks was experienced by 27% of patients. Those are very encouraging results and align very well with what was seen in ACHIEVE I and ACHIEVE II.”
At the 2020 American Headache Society (AHS) Annual Scientific Meeting, June 13, 2020, Chia-Chun Chiang, MD, presented data on a study that evaluated the real-world efficacy, safety, and tolerability of 3 FDA-approved migraine medications. While the results for rimegepant and lasmiditan are still being analyzed, she and her colleagues noted 18 of 57 (32%) patients had experienced headache freedom at 2 hours after taking ubrogepant for 1 or more attacks.
The treatment was also found to provide pain relief for 1 or more attacks in 41 of the 57 patients (73%). Fatigure was the most common adverse event (AE) that was reported in 22% of patients. Most AEs were mild or moderate in severity. Dr. Chiang, a neurologist at Mayo Clinic in Phoenix, Arizona, told NeurologyLive that she sees similarities with what was observed in the ACHIEVE I and ACHIEVE II clinical trials.
In this interview, she breaks down the results of the trial in full detail, while comparing them to what has been previously observed to this point with ubrogepant.
Chiang C, Starling AJ, Dodick DW. Real world efficacy, tolerability and safety of ubrogepant, rimegepant, and lasmiditan. Headache. 2020;60(S1 suppl). 1—156. doi: 10.1111/head.13854